EGFR and neoplasm: Our study revealed that interaction of IL-26 and EphA3 in TNBC activates AKT and JNK, leading to tumor proliferation by inhibiting EGFR-TKI-provoked PERK-eIF2α-DDIT3 pathway and ER stress-associated cell death.